Clinical trials: Acute Coronary Syndrome
Acute Coronary Syndrome, Chest Pain
Randomized Investigation of Chest Pain Diagnostic Strategies
Clinical decision units (CDUs) improve resource utilization and are a recommended care option by the American College of Cardiology / American Heart Association, but are underutilized in non-low risk chest pain patients due to…
- Trial name
- NCT01035047
- Testing
- Clinical decision unit care, coupled with cardiac MRI
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- Wake Forest University Health Sciences
Sleep Apnea, Heart Failure
Diagnosis and Treatment of Sleep Apnea in the Acute Exacerbation of Heart Failure
Congestive heart failure affects 2.3 percent of the population (approximately 4,900,000) with an incidence of 10 per 1,000 of the population after the age of 65 (1).
- Trial name
- NCT00701038
- Testing
- auto adjusting bi-level positive airway pressure device
- Volunteers
- 54 people
- Sponsor
- Rami Khayat
Acute Coronary Syndrome, Coronary Stent Occlusion
Perioperative Management of Patients With Coronary Stents Undergoing Noncardiac Surgery
The purpose of this study is to evaluate and monitor perioperative management of patients with coronary stents undergoing noncardiac surgery.
- Conditions
- Acute Coronary Syndrome, Coronary Stent Occlusion, Surgery
- Trial name
- RegistStents (NCT01171612)
- Where
- 13 sites in Spain
- Volunteers
- 483 people
- Sponsor
- Corporacion Parc Tauli
Thrombosis, Coronary Artery Disease
Antiplatelet Therapy Guided by Thrombelastography in Patients With Acute Coronary Syndromes (TEGCOR Study)
Personalized treatment approaches and antiplatelet drug choice have been proposed to optimize safety of coronary stenting by reducing heart attacks and repeat interventions while simultaneously minimizing adverse bleeding events.
- Trial name
- NCT01612884
- Testing
- Prasugrel, Clopidogrel
- Where
- 2 sites in United States
- Volunteers
- 67 people
- Sponsor
- Indiana University
Acute Coronary Syndrome
The Impact of Aspirin Dose Modification on the Innate Immune Response - Will Lower Dose Aspirin Therapy Reduce the Response to Endotoxin
Heart attacks are usually caused by clots in a coronary artery, depriving the heart muscle of blood. Platelets are the main type of blood cell causing clots to form and physicians typically give a combination of two anti-platelet…
- Trial name
- WILLOW TREE (NCT03869268)
- Testing
- Aspirin, Ticagrelor
- Where
- United Kingdom
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
Stroke, Ischemic, Acute Coronary Syndrome
PRediction of Acute Coronary Syndrome in Acute Ischemic StrokE
The primary goal of the PRAISE study is to develop a diagnostic algorithm that allows the prediction of acute coronary syndrome in stroke patients with elevated levels of cardiac troponin.
- Trial name
- PRAISE (NCT03609385)
- Testing
- Coronary angiography
- Where
- 28 sites in Germany
- Volunteers
- 254 people
- Sponsor
- Charite University, Berlin, Germany
Acute Coronary Syndrome
Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS
A placebo-controlled, randomized, double-blind, parallel group, phase III multicenter study in subjects recently hospitalized for ACS and with the appropriate genetic profile.
- Trial name
- dal-GenE (NCT02525939)
- Testing
- dalcetrapib
- Where
- 557 sites in United States, Argentina and 30 more
- Volunteers
- 6,147 people
- Sponsor
- DalCor Pharmaceuticals
Acute Coronary Syndrome
A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome
The purpose of this study is to estimate the risk of bleeding with rivaroxaban, compared with acetylsalicylic acid (ASA), in addition to a single antiplatelet/ platelet adenosine diphosphate P2Y12 receptor antagonist (P2Y12…
- Trial name
- GEMINI ACS 1 (NCT02293395)
- Testing
- Acetylsalicylic acid, Rivaroxaban, Clopidogrel
- Where
- 259 sites in United States, Argentina and 18 more
- Volunteers
- 3,037 people
- Sponsor
- Janssen Research & Development, LLC
Acute Coronary Syndrome, Myocardial Infarction
An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome
The purpose of this study is to determine whether rivaroxaban in addition to standard care reduces the risk of the composite of cardiovascular death, myocardial infarction, or stroke in patients with a recent acute coronary…
- Conditions
- Acute Coronary Syndrome, Myocardial Infarction, Myocardial Ischemia, Unstable Angina
- Trial name
- NCT00809965
- Testing
- Rivaroxaban 2.5 mg, Rivaroxaban 5 mg, Standard of care
- Where
- 556 sites in United States, Argentina and 41 more
- Volunteers
- 15,526 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Acute Coronary Syndrome
Evolocumab in Patients With Acute MI
Vascular and myocardial inflammation are significantly increased in Acute Coronary Syndrome (ACS) patients, are closely correlated to LDL-C levels, and are associated with these adverse consequences in the post-ACS patient…
- Trial name
- EVACS II (NCT04082442)
- Testing
- Evolocumab
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Johns Hopkins University
Acute Coronary Syndrome
A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects
This study will evaluate the relative efficacy and safety of prasugrel and clopidogrel in a medically managed Unstable Angina/Non-ST-Elevation Myocardial Infarction (UA/NSTEMI) acute coronary syndrome (ACS) population (that is…
- Trial name
- TRILOGY ACS (NCT00699998)
- Testing
- Clopidogrel, Prasugrel, Commercially-available Aspirin
- Where
- 688 sites in United States, Argentina and 51 more
- Volunteers
- 9,326 people
- Sponsor
- Eli Lilly and Company
Coronary Artery Disease
Study Effect of VIA-2291 on Vascular Inflammation
This is a dose ranging study to compare the effect of VIA-2291 vs. Placebo on various inflammatory biomarkers in patients with recent acute coronary events
- Trial name
- NCT00358826
- Testing
- VIA-2291
- Where
- 12 sites in United States, Canada
- Volunteers
- 191 people
- Sponsor
- Tallikut Pharmaceuticals, Inc.
Post Acute Coronary Syndrome, Myocardial Ischemia
Efficacy and Safety of Aliskiren and Valsartan Versus Placebo in Patients Stabilized Following an Acute Coronary Syndrome
The purpose of this study is to test the hypothesis that the inhibition of the renin-angiotensin-aldosterone system (RAAS) with the angiotensin receptor blocker valsartan or the renin antagonist aliskiren will improve ventricular…
- Trial name
- NCT00409578
- Testing
- Aliskiren 300 mg, Valsartan 320 mg, Aliskiren/valsartan 300/320 mg
- Where
- 11 sites in United States, Belgium and 9 more
- Volunteers
- 1,101 people
- Sponsor
- Novartis
Acute Coronary Disease, Angina Unstable
Clopidogrel Optimal Loading Dose Usage to Reduce Recurrent EveNTs/Optimal Antiplatelet Strategy for InterventionS
The purpose of this study is to evaluate whether a higher dosage of clopidogrel with aspirin (two doses) will decrease the risk of ischemic complications (cardiac death (CV death), myocardial infarction (MI), stroke) after a…
- Trial name
- CURRENT/OASIS7 (NCT00335452)
- Testing
- Clopidogrel, acetylsalicyclic acid (ASA)
- Where
- 38 sites in United States, Argentina and 36 more
- Volunteers
- 25,086 people
- Sponsor
- Sanofi
Myocardial Infarction, Acute Coronary Syndromes
Shortened Aggrastat® Versus Integrilin in Percutaneous Coronary Intervention
The purpose this study is to assess whether a tirofiban regimen of a high-dose bolus plus a shortened infusion duration compared to label-dosing eptifibatide in patients undergoing percutaneous coronary intervention (PCI) is…
- Conditions
- Myocardial Infarction, Acute Coronary Syndromes, Unstable Angina
- Trial name
- SAVI-PCI (NCT01522417)
- Testing
- Short Tirofiban, Eptifibatide, Long Tirofiban
- Where
- 13 sites in United States
- Volunteers
- 535 people
- Sponsor
- Medicure
Acute Coronary Syndrome, Lipid Disorder
Polypill in Acute Coronary Syndrome
Acute coronary syndromes (ACS) represent a major contributor to mortality, morbidity, and healthcare costs. Effective therapies are widely available; however, adherence is low.
- Conditions
- Acute Coronary Syndrome, Lipid Disorder, Coronary Artery Disease
- Trial name
- POLY-ACS (NCT05514938)
- Testing
- Polypill, Usual Care (individual medications prescribed by primary cardiologist)
- Where
- 2 sites in United States
- Volunteers
- 140 people
- Sponsor
- University of Texas Southwestern Medical Center
Acute Coronary Syndrome, Angioplasty, Transluminal, Percutaneous Coronary
Early Use of Rosuvastatin in Acute Coronary Syndromes: Targeting Platelet-Leukocyte Interactions
The central hypothesis for this work is that platelet - leukocyte interactions play a critical role in the pathogenesis of acute ischemic events.
- Conditions
- Acute Coronary Syndrome, Angioplasty, Transluminal, Percutaneous Coronary, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Blood Platelets
- Trial name
- NCT01241903
- Testing
- rosuvastatin
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Susan Smyth
Acute Coronary Syndrome
Evolocumab in Acute Coronary Syndrome
Vascular and myocardial inflammation are significantly increased in Acute Coronary Syndrome (ACS) patients, are closely correlated to LDL-C levels, and are associated with these adverse consequences in the post-ACS patient…
- Trial name
- EVACS (NCT03515304)
- Testing
- Evolocumab
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Johns Hopkins University
Acute Coronary Syndrome
Phase III Acute Coronary Syndrome
The purpose of this study is to determine if apixaban is superior to placebo for preventing cardiovascular death, non-fatal myocardial infarction, or ischemic stroke in subjects with a recent acute coronary syndrome
- Trial name
- APPRAISE-2 (NCT00831441)
- Testing
- Apixaban
- Where
- 1,012 sites in United States, Argentina and 38 more
- Volunteers
- 7,484 people
- Sponsor
- Bristol-Myers Squibb
Acute Coronary Syndrome
AngioSeal Versus Radial Approach in Acute Coronary Syndrome
Among non-ST-segment elevation acute coronary syndrome patients submitted to early invasive strategy and randomized for the transfemoral or transradial approach, the AngioSeal vascular closure device would decrease the prevalence…
- Trial name
- ARISE (NCT01653587)
- Testing
- Percutaneous coronary intervention
- Where
- Brazil
- Volunteers
- 240 people
- Sponsor
- Irmandade Santa Casa Misericórdia Marília